- Previous Close
41.00 - Open
41.00 - Bid 37.00 x --
- Ask 38.00 x --
- Day's Range
37.00 - 41.00 - 52 Week Range
37.00 - 89.00 - Volume
2,360,800 - Avg. Volume
558,306 - Market Cap (intraday)
3.261B - Beta (5Y Monthly) 1.35
- PE Ratio (TTM)
-- - EPS (TTM)
-16.51 - Earnings Date May 8, 2025 - May 12, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
BrightPath Biotherapeutics Co., Ltd. engages in the development of cancer immunotherapy drugs in Japan. It is developing GRN-1201, a cancer peptide vaccine candidate that is in Phase II clinical trials for the treatment of non-small cell lung cancer, as well as in Phase I clinical trials to treat melanoma. The company is also developing BP2201, a product candidate in Phase I clinical trials to target cancer antigens in various types of cancer; and BP2301, a product candidate in Phase I clinical trials for the treatment of solid tumors sarcoma and gynecological cancers. In addition, its product candidates in preclinical trials include BP1202 that targets CD39; BP1210, which suppresses T cell cytotoxicity; BP1212 to inhibit TIM-3 and CD39; BP1209 to target tumor-specific neoantigens; and BP1200 to target CD73. The company was formerly known as GreenPeptide Co., Ltd. and changed its name to BrightPath Biotherapeutics Co., Ltd. in July 2017. BrightPath Biotherapeutics Co., Ltd. was incorporated in 2003 and is headquartered in Tokyo, Japan.
www.brightpathbio.comRecent News: 4594.T
View MorePerformance Overview: 4594.T
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is Nikkei 225 (^N225) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 4594.T
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 4594.T
View MoreValuation Measures
Market Cap
3.26B
Enterprise Value
2.05B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
36.91k
Price/Book (mrq)
2.64
Enterprise Value/Revenue
24.37k
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-20.57%
Return on Equity (ttm)
-38.44%
Revenue (ttm)
262M
Net Income Avi to Common (ttm)
-1.87B
Diluted EPS (ttm)
-16.51
Balance Sheet and Cash Flow
Total Cash (mrq)
5.23B
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--